REGENXBIO (RGNX)
Develops one-time AAV gene therapies while licensing its NAV vector platform.
$7.47
vs last close−0.68 (−8.33%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 82.37% | 42.59M shares | |
|---|---|---|---|
| 176 holders · as of Jun 30, 2026 | |||
| Insiders | 3.92% | 2.03M shares | |
| 16 holders · as of Sep 3, 2026 | |||
| Strategic holders | 4.25% | 2.20M shares | |
| 1 holder · as of Apr 7, 2023 | |||
| Other | 9.46% | 4.89M shares | |
| remainder | |||
51.70M company shares as of Sep 16, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (66.01M in the company's Sep 23, 2026 report, 51.70M elsewhere); stakes use the report.
13F, as of Jun 30, 2026
176 holders · 42.59M shares · 27 new positions · 89 increased · 52 reduced · 38 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.40M | 12.37% | +614.6K | Aug 7, 2026 |
| Redmile Group, LLC | 4.37M | 8.45% | 0 | Aug 14, 2026 |
| State Street Corp | 2.97M | 5.75% | +239.7K | Aug 7, 2026 |
| JPMorgan Chase & Co | 2.21M | 4.28% | −1.27M | Aug 12, 2026 |
| Vanguard Capital Management LLC | 2.11M | 4.08% | +100.4K | Aug 13, 2026 |
| Morgan Stanley | 1.95M | 3.78% | −112.9K | Aug 13, 2026 |
| Goldman Sachs Group Inc | 1.42M | 2.75% | −418.0K | Aug 14, 2026 |
| AQR Capital Management LLC | 1.38M | 2.67% | +326.6K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Redmile Group, LLC | 9.90% | 5.06M | 13G | Aug 14, 2025 |
| BlackRock, Inc. | 7.30% | 3.68M | 13G | Apr 24, 2025 |
| State Street Corporation | 5.30% | 2.73M | 13G | May 12, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 27, 2026 | Gregory Austin Ciongolidirector | Purchase | 53,407 | $9.36 | 118,035 |
| Aug 26, 2026 | Gregory Austin Ciongolidirector | Purchase | 49,196 | $9.14 | 64,628 |
| Jul 2, 2026 | Steve Pakolaofficer: Chief Medical Officer | Sale | 2,161 | $13.64 | 213,009 |
| Jul 1, 2026 | Steve Pakolaofficer: Chief Medical Officer | Sale | 36,725 | $12.86 | 213,009 |
| Jun 29, 2026 | Steve Pakolaofficer: Chief Medical Officer | Sale | 19,608 | $11.04 | 213,009 |
| May 11, 2026 | Steve Pakolaofficer: Chief Medical Officer | Sale | 15,309 | $11.02 | 232,617 |
| Mar 10, 2026 | Steve Pakolaofficer: Chief Medical Officer | Sale | 5,124 | $10.35 | 247,926 |
| Oct 9, 2025 | Curran Simpsondirector, officer: Chief Executive Officer | Sale | 20,811 | $12.62 | 216,162 |
| Sep 29, 2025 | Curran Simpsondirector, officer: Chief Executive Officer | Sale | 7,624 | $10.03 | 236,973 |
House and Senate disclosures
Not reported.